AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2022-11-10 |
2022-09 |
-0.77 |
N/A |
N/A |
N/A |
2022-08-12 |
2022-06 |
-0.68 |
N/A |
N/A |
N/A |
2022-05-16 |
2022-03 |
-0.34 |
N/A |
N/A |
N/A |
2022-03-28 |
2021-12 |
0 |
N/A |
N/A |
N/A |
2021-11-10 |
2021-09 |
-0.51 |
N/A |
N/A |
N/A |
2021-08-11 |
2021-06 |
0 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2022-11-11 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2021-10-11 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2022-08-25 |
BLATTNER GREGORY JAMES |
Director |
12.41K |
Stock Award(Grant) |
2022-08-25 |
DUDLEY ROBERT FREDERICK |
Director |
12.41K |
Stock Award(Grant) |
2022-12-13 |
HAYES ANTHONY |
Chief Executive Officer |
176.68K |
Purchase |
2022-08-25 |
LEDWICK TIM S |
Director |
12.83K |
Stock Award(Grant) |
2022-08-25 |
LEMIRE PAUL |
Director |
12.41K |
Stock Award(Grant) |
2022-08-25 |
VANDER ZANDEN ROBERT J |
Director |
12.70K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2022-09-29 |
Vanguard Group, Inc. (The) |
193.54K |
689.01K |
3.53% |
2022-09-29 |
Two Sigma Advisers, LP |
86.70K |
308.65K |
1.58% |
2022-09-29 |
Blackrock Inc. |
75.28K |
267.98K |
1.37% |
2022-09-29 |
Dimensional Fund Advisors LP |
57.85K |
205.94K |
1.05% |
2022-09-29 |
Two Sigma Investments, LP |
53.60K |
190.80K |
0.98% |
2022-09-29 |
Geode Capital Management, LLC |
43.41K |
154.54K |
0.79% |
Report Date |
Organization |
Position |
Value |
Percentage |
2022-09-29 |
Vanguard Total Stock Market Index Fund |
111.01K |
395.21K |
2.02% |
2022-09-29 |
Vanguard Extended Market Index Fund |
77.59K |
276.22K |
1.41% |
2022-07-30 |
Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF |
25.46K |
90.63K |
0.46% |
2022-10-30 |
Fidelity Extended Market Index Fund |
23.58K |
83.94K |
0.43% |
2022-07-30 |
DFA U.S. Small Cap Series |
8.87K |
31.58K |
0.16% |
2022-10-30 |
Fidelity Total Market Index Fund |
7.42K |
26.41K |
0.14% |
Dividend |
Date |
0.0389 |
1980-05-12 |
0.0778 |
1979-05-14 |
0.0667 |
1978-05-15 |
Split |
Date |
1 : 17 |
2022-06-07 |
1113 : 1000 |
2019-10-28 |
1 : 4 |
2019-05-10 |
1 : 19 |
2016-03-04 |
1 : 20 |
2012-09-24 |
1 : 10 |
2011-05-09 |